Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$46.57 USD
-0.46 (-0.97%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $46.60 +0.04 (0.08%) 4:18 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Soleno Therapeutics, Inc. (SLNO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$66.00 | $93.00 | $40.00 | 40.37% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Soleno Therapeutics, Inc. comes to $66.00. The forecasts range from a low of $40.00 to a high of $93.00. The average price target represents an increase of 40.37% from the last closing price of $47.02.
Analyst Price Targets (6 )
Broker Rating
Soleno Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SLNO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/21/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
8/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/10/2024 | Robert W. Baird & Co. | Brian P Skorney | Not Available | Strong Buy |
5/10/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
11/21/2023 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $66.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 97 of 253 |
Current Quarter EPS Est: | -0.62 |